The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that ...
Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to ...
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...
Drugmaker Johnson and Johnson is suing the Department of Health and Human Services and the Health Resources and Services Administration for blocking its new 340B rebate model, and is seeking to verify ...
The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...
Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we ...
California is poised to pass a ballot measure aimed at imposing 340B spending restrictions for certain healthcare entities participating in the ...
Johnson & Johnson on Tuesday sued the Biden administration in a controversy over how it distributes rebates under the federal ...
Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...
Discover how the 340B drug pricing program, intended to help low-income patients, has become a system of abuse and misuse ...
Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out ...
In its lawsuit, the company argued that HRSA has wrongfully interpreted a federal law concerning the use of rebates in the 340B Drug Pricing Program. J&J recently sought to change payment terms for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback